Sentences with phrase «results of lung cancer patients»

Dr. Glen Weiss, M.D., M.B.A., is the first author of the study abstract: Phase Ib / II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) 1 prior line of therapy.

Not exact matches

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90 % disease control and 59 % response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

Many lung cancer trials have traditionally excluded patients with brain metastases at baseline, expecting that the presence of metastases would create negative results that could in turn create the appearance of drug failure.

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

Trinh and his colleagues used Surveillance, Epidemiology, and End Results Program (SEER) data to look at more than 2.5 million Asian American patients who were diagnosed with lung, breast, prostate or colorectal cancer (the three leading causes of cancer - related mortality within each gender) between 1991 and 2007.

«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»

Ceritinib provides longer progression - free survival than chemotherapy in crizotinib - pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND - 5 study presented at the ESMO 2016 Congress in Copenhagen.

As a result, this group succeeded in isolating ORs which respond to three types of volatile organic compounds (2 - pentanone, pyridine, 2 - butanone) respectively in urine samples from lung cancer patients.

The results of these animal trials may eventually help patients with colon, rectum, stomach, breast, or lung cancer.

A new drug that targets not only common cancer - causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I / II clinical trial.

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.

Although the patients» exposure to cigarettes and other hydrocarbon sources was not integrated with the results, the idea of a marker for lung cancer held up.

The results published in the October issue of the Journal of Thoracic Oncology, the official journal for the International Association for the Study of Lung Cancer, show that TNI levels were undetectable in all patients before RT and increased slightly in 2 patients following RT but these returned to undetectable levels at the first follow - up.

Overall, results also showed that it took a month and a half to more than 6 months for many patients to undergo surgery after an initial x-ray displayed signs of possible lung cancer.

With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery.

«Our results suggest that administering p38 inhibitors to certain patients with advanced stages of colon cancer or with established metastases could be counterproductive and may enhance cell acquisition of lung colonization potential,» says Gomis.

An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that, among 236 patients with various types of cancer, the treatment shrank tumors in 28 percent of melanoma patients, 30 percent of patients with kidney cancer, and 18 percent of patients with advanced non-small cell lung cancer.

A 2012 paper co-authored by Ingber, for example, reported results from a study of a lung - on - a-chip model of pulmonary edema, which can affect cancer patients taking the drug interleukin - 2.

Now, on Nov. 5, a news story likened those findings to the results of a large trial by the National Cancer Institute, which showed that CT scans reduced mortality rates among the highest - risk lung cancer patients by 20 peCancer Institute, which showed that CT scans reduced mortality rates among the highest - risk lung cancer patients by 20 pecancer patients by 20 percent.

These results should support the idea that IMRT is the radiation therapy of choice for lung cancer patients as well.

If clinical trials of anti-PD-1 continue to show promising results, cancer patients may soon have access to another powerful immunotherapy for the treatment of numerous cancers, including melanoma, non-small cell lung cancer, and other solid tumors.

Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial